| Code | CSB-RA005268MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Ruxoprubart, targeting complement factor B (CFB), a critical serine protease in the alternative pathway of the complement system. CFB combines with complement factor 3b (C3b) to form the C3 convertase, which amplifies complement activation and plays a central role in innate immunity. Dysregulation of CFB activity has been implicated in various complement-mediated disorders, including age-related macular degeneration, atypical hemolytic uremic syndrome, C3 glomerulopathy, paroxysmal nocturnal hemoglobinuria, and IgA nephropathy, making it an important therapeutic target for complement-related pathologies.
Ruxoprubart is a humanized monoclonal antibody designed to inhibit CFB, thereby modulating alternative complement pathway activation. This biosimilar antibody serves as a valuable research tool for investigating complement biology, studying the pathophysiology of complement-driven diseases, and exploring potential therapeutic interventions targeting the alternative pathway. It enables researchers to examine CFB-mediated mechanisms in various disease models and advance understanding of complement system regulation in inflammatory and autoimmune conditions.
There are currently no reviews for this product.